--:-- ET
Home›ETF directory›185680
ETF analysis

KODEX US S&P Bio ( Synthetic ) (185680) holdings & weights

Per-holding contribution · concentration · sector skew — a deep read

KR-listedAs of 2026-10-15
IndexS&P Biotechnology Select Industry Index
Annual fee0.25%
Net assetsKRW 41,857.75

Fund overview

This is a Korea-listed ETF from 삼성자산운용. It tracks the S&P Biotechnology Select Industry Index. Key facts — expense ratio 0.25%; net assets about KRW 41,857.75. Its 1-year return is +25.81%.

Index tracked
S&P Biotechnology Select Industry Index
Provider
삼성자산운용
Expense ratio
0.25%
Net assets (AUM)
KRW 41,857.75
1-month return
-12.57%
1-year return
+25.81%
Holdings
5
52-week range
31,790–55,395
Fund details

Fund overview

This is a Korea-listed ETF from 삼성자산운용. It tracks the S&P Biotechnology Select Industry Index. Key facts — expense ratio 0.25%; net assets about KRW 41,857.75. Its 1-year return is +25.81%.

Index tracked
S&P Biotechnology Select Industry Index
Provider
삼성자산운용
Expense ratio
0.25%
Net assets (AUM)
KRW 41,857.75
1-month return
-12.57%
1-year return
+25.81%
Holdings
5
52-week range
31,790–55,395

157 identified stocks · net exposure / NAV 8.86%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Underlying allocation is estimated using XBI (2026-10-16). Cash and unallocated contracts are excluded from stock attribution.

Weight and calculation basis

157 identified stocks · net exposure / NAV 8.86%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Underlying allocation is estimated using XBI (2026-10-16). Cash and unallocated contracts are excluded from stock attribution.

Investor net buying

Latest-session net buying by foreigners, institutions and retail (positive = net buy, negative = net sell).

−180 sh
Foreign
−323 sh
Institution
+503 sh
Retail
0.12%
Foreign ownership
DateChangeForeignInst.Retail
10/19-3.48%−180 sh−323 sh+503 sh
10/16+2%+83 sh−552 sh−52 sh
10/15-0.37%−36 sh+1.1K sh−1.0K sh
10/14-3.04%−41 sh+211 sh−170 sh
10/13-1.45%−7 sh+249 sh−242 sh
Investor flows

Investor net buying

Latest-session net buying by foreigners, institutions and retail (positive = net buy, negative = net sell).

−180 sh
Foreign
−323 sh
Institution
+503 sh
Retail
0.12%
Foreign ownership
DateChangeForeignInst.Retail
10/19-3.48%−180 sh−323 sh+503 sh
10/16+2%+83 sh−552 sh−52 sh
10/15-0.37%−36 sh+1.1K sh−1.0K sh
10/14-3.04%−41 sh+211 sh−170 sh
10/13-1.45%−7 sh+249 sh−242 sh
—
Holdings not priced
18.1%
Top-10 weight
112
Concentration HHI (Low)
Health Care
Top sector

We have this ETF's holdings, but the prices for those particular listings are outside our quote coverage (currently Korea- and US-listed securities). So today's contribution and return are not computed — showing 0% would claim it did not move, which is a different statement. The holdings and weights below follow the calculation basis above.

Today's summary

Its top 10 holdings make up about 18.1% of the fund. The concentration index (HHI) is 112 — Low — evenly diversified, and the largest sector is Health Care (99%). The higher the concentration, the more one stock or sector drives the whole ETF's return.

Structural health

A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.

63/ 100
BSound structure
DiversificationHHI 112100

Concentration is below 1,500 (112), so no single holding dominates.

Sector balanceHealth Care 99%0

Health Care alone is 99%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.

Cost0.25%/yr83

0.25% a year is typical. Held ten years, roughly 2.5% goes to fees.

Fund sizeKRW 41,8580

Net assets of KRW 41,858 are small. Thin funds trade at wider spreads, and very small ones get closed or merged.

Structural simplicityPhysical, 1x100

A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.

Concentration and diversification

Structural health

A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.

63/ 100
BSound structure
DiversificationHHI 112100

Concentration is below 1,500 (112), so no single holding dominates.

Sector balanceHealth Care 99%0

Health Care alone is 99%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.

Cost0.25%/yr83

0.25% a year is typical. Held ten years, roughly 2.5% goes to fees.

Fund sizeKRW 41,8580

Net assets of KRW 41,858 are small. Thin funds trade at wider spreads, and very small ones get closed or merged.

Structural simplicityPhysical, 1x100

A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.

Top 20 holdings

2 derivative positions are excluded. Stock contributions do not explain the entire ETF return.

Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.

Normalized to 100% of analysed positions

Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.

Tile size = weight, colour = the day's return (deeper = larger). Covers the top 30 holdings, 4.1% of the fund. Labels are dropped where a tile is too small; hover any tile for its name and figures.
#HoldingWeight
1MODERNAMRNA2.53%
2NATERANTRA1.87%
3ABBVIEABBV1.79%
4HALOZYME THERAPEUTICSHALO1.78%
5AMGENAMGN1.74%
6BIOGENBIIB1.74%
7GILEAD SCIENCESGILD1.69%
8EXELIXISEXEL1.68%
9TWIST BIOSCIENCETWST1.66%
10UNITED THERAPEUTICSUTHR1.65%
11IOVANCE BIOTHERAPEUTICSIOVA1.63%
12TG THERAPEUTICSTGTX1.55%
13REGENERON PHARMACEUTICALSREGN1.54%
14VERTEX PHARMACEUTICALSVRTX1.51%
15SPYRE THERAPEUTICSSYRE1.45%
16KRYSTAL BIOTECHKRYS1.43%
17ALKERMESALKS1.43%
18CRISPR THERAPEUTICSCRSP1.42%
19ALNYLAM PHARMACEUTICALSALNY1.41%
20INCYTEINCY1.41%

Holdings below 0.5% or outside the top list are folded into “Others” and omitted above.

Where the weight sits — sector mix

Listed equity weights summed by sector and normalized to 100%. Each band is one sector's share.

Health Care99.4%
Financials0.6%
Industry breakdown
Biotechnology: Pharmaceutical Preparations53.8%
Biotechnology: Biological Products (No Diagnostic Substances)35.5%
Medical Specialities5.8%
Biotechnology: In Vitro & In Vivo Diagnostic Substances2.5%
Biotechnology: Commercial Physical & Biological Resarch1.9%
Finance: Consumer Services0.6%
Medical/Dental Instruments0.1%
Concentration at a glanceHHI 112well spread
spread1,0001,8002,500concentrated

HHI sums the squared weights. The more it leans on a few names, the higher it goes — and the more the whole ETF moves with them.

How concentrated is it

Concentration (HHI) is low at 112, with the top 10 holdings at just 18.1% of equity weight. No single name can dominate the fund.

Good for damping single-stock risk — and equally, a big winner inside gets diluted.

HHI squares each weight and sums them: 10,000 means one stock is everything, and the more evenly spread the holdings, the closer it falls to zero.

Where the sector weight sits

By sector, Health Care alone is 99% — whatever the fund is called, this is a bet on that industry.

Bad news for the sector moves the whole fund. Worth checking against anything else you hold in the same space.

Weights above sum the individually listed equities and normalize that equity total to 100%.

How much it overlaps others

It shares 70% of its holdings with 419430 (4 names in common) — close to half the same companies.

Own both and the diversification is thinner than it looks.

What it is made of

Equities are 8.9% of the fund, the rest swaps and cash — index exposure built synthetically rather than by owning the shares, which adds counterparty risk.

The expense ratio is 0.25% a year. Funds tracking the same index tend to perform alike, which makes the fee one of the few things that reliably separates them over time.

This page is not investment advice. Investment decisions and responsibility are your own.

185680 comments

Leave a one-line take on KODEX 미국S&P바이오(합성). No account — just a nickname and a code to delete it later.

Loading…

Similar ETFs

Picked by how much their actual holdings overlap. The higher the overlap, the less diversification you get from owning both.